LinkedInFacebookTwitterRssEmail
(832) 968-8698|sales@avancebio.com

News

28 06, 2022

Sana Biotechnology to expand its manufacturing, advance cell-based therapies in neurological disorders

2024-07-10T19:30:27+00:00

The University of Rochester Medical Center (URMC) and Sana Biotechnology have entered into an agreement which will allow Sana to expand its manufacturing footprint and create new job opportunities in Rochester. Sana, a company focused on creating and delivering engineered cells as medicines, also operates in Seattle, Cambridge, and South San Francisco. The company has programs [...]

Sana Biotechnology to expand its manufacturing, advance cell-based therapies in neurological disorders2024-07-10T19:30:27+00:00
10 05, 2022

FDA issues new draft guidelines on genome editing and CAR-T therapy

2024-07-13T13:28:34+00:00

On March 15th, 2022 the FDA is announcing the availability of two draft guidance documents: “Human Gene Therapy Products Incorporating Human Genome Editing,” and “Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products.” The draft guidance, “Human Gene Therapy Products Incorporating Human Genome Editing,” is intended to provide recommendations to sponsors [...]

FDA issues new draft guidelines on genome editing and CAR-T therapy2024-07-13T13:28:34+00:00
4 05, 2022

FDA fast tracks unique next-generation gene-edited therapy for sickle cell disease patients

2024-07-10T19:30:59+00:00

Graphite Bio is a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases. The FDA has just granted Fast Track Designation to GPH101 for the treatment of sickle cell disease (SCD). GPH101 is an investigational next-generation gene-edited autologous [...]

FDA fast tracks unique next-generation gene-edited therapy for sickle cell disease patients2024-07-10T19:30:59+00:00
16 02, 2021

Avance Biosciences™ Expanding Houston Campus

2024-07-10T19:33:13+00:00

HOUSTON, Feb. 16, 2021 /PRNewswire/ -- Avance Biosciences™, a leading CRO providing GLP/GMP-compliant assay development, assay validation, and sample testing services supporting biological drug development and manufacturing, announced today that its Houston facility, which successfully passed an inspection by the U.S. Food and Drug Administration in Oct 2018, is undergoing major expansion to handle rapidly growing demand for their services. [...]

Avance Biosciences™ Expanding Houston Campus2024-07-10T19:33:13+00:00
7 12, 2020

Avance Biosciences™ Recognized as Top 10 Genomics Solutions Company

2022-05-05T13:21:09+00:00

Pharm Tech Outlook, a highly respected pharmaceutical/biotech industry magazine, has recognized Avance Biosciences™ as a top 10 Genomics Solutions Company for 2020. Genomic technologies and their usage have seen extensive growth in the past decade. Over the years, these technologies have evolved significantly and can now be used [...]

Avance Biosciences™ Recognized as Top 10 Genomics Solutions Company2022-05-05T13:21:09+00:00
30 10, 2018

Avance Biosciences™ Completes Successful FDA Inspection

2023-04-11T14:25:35+00:00

HOUSTON, Oct. 30, 2018 - Avance Biosciences™, Inc., a leading biological testing company supporting drug development and manufacturing, announced today that its Houston facility was inspected by the U.S. Food and Drug Administration on October 01 through October 04, 2018.  This inspection focused on the firm’s quality management system, operation procedures, and data integrity, as [...]

Avance Biosciences™ Completes Successful FDA Inspection2023-04-11T14:25:35+00:00
25 03, 2012

Avance Biosciences™ Signed MSA

2024-11-12T13:49:51+00:00

In the week of March 18, 2012, Avance Biosciences™ entered a Master Service Agreement (MSA) with a global leader in custom biologics manufacturing. Based on this agreement, Avance Biosciences™ will provide its GMP level Cell Bank Characterization services, including DNA Sequencing, qPCR, Southern blot and other molecular biological methods, to characterize the Master Cell Bank (MCB), Working Cell Bank (WCB), and End of Production Cells (EOPC) submitted by the clients.

Avance Biosciences™ Signed MSA2024-11-12T13:49:51+00:00
5 07, 2011

New Website – Avance Biosciences™ Inc.

2024-11-12T13:50:03+00:00

  To Our Esteemed Customers and Friends: We would like to bring to your attention that Avance Biosciences™ Inc. has been formed by a group of experienced genomic scientists, quality professionals, biotechnology services experts, and enthusiastic investors.  The founders of the company, combined, have more than 100 years of experience in the genomics and biotechnology [...]

New Website – Avance Biosciences™ Inc.2024-11-12T13:50:03+00:00
Go to Top